p-chlorophenylboricacid | 274251-56-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: p-chlorophenylboricacid
• 英文别名: boric acid tri-(p-chlorophenyl)-ester；4-chlorophenylboronic acid；4-chlorophenyl boric acid；boronic acid 4-chlorophenyl monoester；p-Chlorophenylboric acid；(4-chlorophenoxy)boronic acid
• CAS: 274251-56-8
• 化学式: C₆H₆BClO₃
• 分子量: 172.376
• InChiKey: CFPFMAGBHTVLCZ-UHFFFAOYSA-N

物化性质

• 熔点：
  275 °C
• 沸点：
  258-260 °C(Press: 5 Torr)
• 密度：
  1.369±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.69
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  p-chlorophenylboricacid 生成 2-ethoxy-5-(4-chlorophenyl)benzaldehyde
  参考文献：
  名称：

  EP1323713

  摘要：

  公开号：
• 作为产物：
  描述：

  正丁基锂 、 硼酸三异丙酯 、 盐酸 在 4-chloro-bromophenyl 、 氩 、 甲苯 、 Brine 、 Sodium sulfate-III 作用下， 以 甲苯 、 四氢呋喃 、 水 为溶剂， 反应 2.0h， 以to give 4-chlorophenylboric acid (48 g) as a solid的产率得到p-chlorophenylboricacid
  参考文献：
  名称：

  Compounds and therapeutic use thereof for protein kinase inhibition

  摘要：

  本发明提供了具有以下式的新化合物:还公开了包含该化合物的制药组合物，使用该化合物治疗癌症的方法以及制备该化合物的方法。本发明的新化合物被发现能够抑制蛋白激酶，特别是检查点激酶Chk1/Chk2。

  公开号：

  US09249154B2

文献信息

• Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040209865A1

  公开（公告）日：2004-10-21

  The present invention relates to alkyne compounds of general formula I 1 wherein the groups and residues A, B, W, X, Y, Z, R 1 and R 2 have the meanings given in claim 1 . The invention further relates to pharmaceutical compositions containing at least one alkyne according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的炔烃化合物 1 其中基团和残基A、B、W、X、Y、Z、R 1 和R 2 具有权利要求中给出的含义。本发明还涉及含有根据本发明至少一种炔烃的药物组合物。鉴于它们的MCH受体拮抗活性，根据本发明的药物组合物适用于治疗代谢紊乱和/或进食紊乱，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。
• Pyrimidine compounds
  申请人：Hoffmann-La Roche Inc.

  公开号：US05688798A1

  公开（公告）日：1997-11-18

  Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2 each individually are lower-alkyl or amino, A is ##STR2## B is hydrogen in A.sup.4, A.sup.5 and A.sup.6 ; ##STR3## in A.sup.1 -A.sup.6 ; lower-alkoxy in A.sup.4 -A.sup.6 ; and lower-alkyl, styryl, phenylethynyl or benzoyloxy-lower-alkyl in A.sup.1 and A.sup.2 ; n is 0, 1 or 2; m, p are, independently 0, 1 and R.sup.3, R.sup.4, R.sup.5 and R.sup.6 each independently are hydrogen, halogen, lower-alkyl, trifluoromethyl, lower-alkoxy or nitro, and pharmaceutically acceptable acid addition salts thereof. These compounds are useful in the control or prevention of illnesses which are caused by disorders of the dopamine system, in particular psychotic illnesses such as schizophrenia.

  该公式化合物的化合物##STR1##其中R.sup.1和R.sup.2分别为较低的烷基或氨基，A为##STR2## B为A.sup.4中的氢，A.sup.5和A.sup.6；##STR3##在A.sup.1-A.sup.6中；A.sup.4-A.sup.6中的较低烷氧基；以及A.sup.1和A.sup.2中的较低烷基，苯乙烯基，苯乙炔基或苯甲酰氧基较低烷基；n为0、1或2；m、p分别为0、1，R.sup.3、R.sup.4、R.sup.5和R.sup.6各自独立为氢、卤素、较低烷基、三氟甲基、较低烷氧基或硝基，以及其药学上可接受的酸盐。这些化合物在控制或预防由多巴胺系统紊乱引起的疾病中特别有用，特别是精神分裂症等精神疾病。
• Biphenyl derivatives and the use thereof as integrin inhibitors
  申请人：——

  公开号：US20040010023A1

  公开（公告）日：2004-01-15

  The invention relates to novel biphenyl derivatives of the general formula (I), wherein R 4 represents an aromatic heterocycle, and to the physiologically acceptable salts or solvates thereof. The inventive compounds are integrin inhibitors and are used for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammations, tumors, osteoporosis, infections and restenosis following angioplasty or for pathological processes that are maintained or propagated by angiogenesis. 1

  该发明涉及一种通式（I）的新型联苯衍生物，其中R4代表芳香杂环，并且其生理上可接受的盐或溶剂化合物。这些创新化合物是整合素抑制剂，用于对抗血栓形成、心肌梗死、冠心病、动脉粥样硬化、炎症、肿瘤、骨质疏松症、感染以及在血管成形术后再狭窄或由血管生成维持或传播的病理过程。
• CARBAZOLE COMPOUND AND USE THEREOF
  申请人：Matsumoto Naoki

  公开号：US20120203010A1

  公开（公告）日：2012-08-09

  A carbazole compound represented by the following formula: wherein, when m=1, n=0, Ar 1 , Ar 2 , Ar 3 and X 2 are C 6-50 aryl or C 4-50 heteroaryl, provided that Ar 1 and Ar 2 , or Ar 3 and X 2 may form together a ring; X 1 ═C 6-50 arylene; R 1 , R 2 , R 4 , R 5 and R 7 are H, halogen, amino, C 1-18 alkyl, C 1-18 alkoxy, C 6-50 aryl or C 4-50 heteroaryl, R 3 and R 6 are H, halogen, C 1-18 alkyl, C 1-18 alkoxy, C 6-50 aryl or C 4-50 heteroaryl; when m=0, n=1-3, Ar 3 , Ar 4 and Ar 5 are C 6-50 aryl or C 4-50 heteroaryl, Ar 4 and Ar 5 may form together a ring; X 1 ═C 1-18 alkyl, C 6-50 aryl or C 4-50 heteroaryl; X 2 ═C 6-50 arylene; R 1 -R 7 are H, halogen, C 1-18 alkyl, C 1-18 alkoxy, C 6-50 aryl or C 4-50 heteroaryl; when m=0, n=0, X 1 ═C 1-18 alkyl, C 6-50 aryl or C 4-50 heteroaryl; Ar 3 and X 2 are C 6-50 aryl or C 4-50 heteroaryl; R 2 ═H, halogen, C 1-18 alkyl, C 1-18 alkoxy; R 1 and R 3 -R 7 are H, halogen, C 1-18 alkyl, C 1-18 alkoxy, C 6-50 aryl or C 4-50 heteroaryl. The carbazole compound is suitable for an organic EL device.

  以下是该化合物的中文翻译：其中，当m=1，n=0时，Ar1、Ar2、Ar3和X2为C6-50芳基或C4-50杂环芳基，前提是Ar1和Ar2，或Ar3和X2可能共同形成一个环；X1=C6-50芳基；R1、R2、R4、R5和R7为H、卤素、氨基、C1-18烷基、C1-18烷氧基、C6-50芳基或C4-50杂环芳基，R3和R6为H、卤素、C1-18烷基、C1-18烷氧基、C6-50芳基或C4-50杂环芳基；当m=0，n=1-3时，Ar3、Ar4和Ar5为C6-50芳基或C4-50杂环芳基，Ar4和Ar5可能共同形成一个环；X1=C1-18烷基、C6-50芳基或C4-50杂环芳基；X2=C6-50芳基；R1-R7为H、卤素、C1-18烷基、C1-18烷氧基、C6-50芳基或C4-50杂环芳基；当m=0，n=0时，X1=C1-18烷基、C6-50芳基或C4-50杂环芳基；Ar3和X2为C6-50芳基或C4-50杂环芳基；R2=H、卤素、C1-18烷基、C1-18烷氧基；R1和R3-R7为H、卤素、C1-18烷基、C1-18烷氧基、C6-50芳基或C4-50杂环芳基。这种咔唑化合物适用于有机EL器件。
• New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20040242572A1

  公开（公告）日：2004-12-02

  The present invention relates to carboxamide compounds of general formula I 1 wherein the groups and residues A, B, W, X, Y, Z, R 1 , R 2 , R 3 and k have the meanings given in claim 1. Moreover the invention relates to process for preparing the above mentioned carboxamides as well as pharmaceutical compositions containing at least one carboxamide according to the invention. In view of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I1的羧酰胺化合物，其中A、B、W、X、Y、Z、R1、R2、R3和k的基团和残基具有权利要求1中所给出的含义。此外，本发明还涉及制备上述羧酰胺化合物的方法，以及含有本发明所述至少一种羧酰胺的制药组合物。基于它们的MCH受体拮抗活性，本发明的制药组合物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症、暴食症、厌食症、暴食症和糖尿病。